AirXpanders' AeroForm® Tissue Expander Technology Showcased at Three International Surgery Conferences

PALO ALTO, Calif., June 22, 2016 /PRNewswire/ -- AirXpanders, Inc., a company developing a novel technology for women undergoing tissue expansion for breast reconstruction following a mastectomy, recently showcased its AeroForm® patient-controlled tissue expander at three prestigious plastic surgery conferences held across Europe and Australia. AirXpanders' AeroForm technology is available in Australia and Europe, and is currently under review with the U.S. Food and Drug Administration.

May 2-6, 2016, AirXpanders attended the Royal Australian College of Surgeons (RACS) Annual Scientific Congress (ASC), the largest annual multi-disciplinary surgical meeting in Australia. The event attracted over 2,000 surgeons, surgical trainees and other health professionals. At the conference, AirXpanders sponsored the Level 1 Oncoplastic Breast Surgery Workshop for breast surgeons and introduced them to AeroForm.

May 19-21, 2016, AirXpanders exhibited at the Paris Breast Rendez-Vous Conference, an event dedicated to reconstructive, oncologic and aesthetic breast surgery. The conference featured more than 500 plastic and reconstructive surgeons, medical oncologists, geneticists and other experts from around the world, meeting to discuss the latest innovations in breast surgery. Dr. Jeffery Ascherman, chief of the division of plastic surgery at Columbia University and principal investigator of the XPAND trial, spoke about his experience with AeroForm in breast reconstruction procedures. He also shared positive clinical results from the XPAND trial, which is the pivotal clinical trial evaluating AeroForm compared to saline expanders.

The following week, on May 25-28, 2016, AirXpanders was at the EURAPS Meeting in Brussels, an event focused on breast surgery and several other areas within the specialty of plastic and reconstructive procedures. AeroForm was showcased, allowing plastic surgeons to gain familiarity with the new technology.

"We believe there is growing momentum around AeroForm during this important phase for the company," said Scott Dodson, AirXpanders president and CEO. "These three events allowed our team to connect with a strong network of experts globally, and we look forward to capitalizing on this increasing interest and excitement as we work toward continued growth both internationally and, post approval, in the United States."

For more information on AeroForm, and to stay up to date on company updates, please visit http://www.airxpanders.com.

About AirXpanders

AirXpanders, Inc. (www.airxpanders.com) is a tissue expansion company focused on the area of breast reconstruction. By employing a revolutionary patient-controlled expander, activated by a wireless remote control, the often painful process of reclaiming one's body after cancer can potentially be eased with this needle-free technology. This technology is easy to use and may enable the patient to proceed to a permanent implant much faster than the current standard of care. AirXpanders is a publically listed company on the Australian Stock Exchange under the symbol AXP and is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital, Shalon Ventures, Correlation Ventures, Western Technology Investments and a number of leading investment firms in Australia, Hong Kong and Singapore. The AeroForm Tissue Expander System is not cleared or approved for use in the United States and is for investigational use only. AeroForm is cleared for commercialization in Europe and in Australia.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future development of AeroForm, including the XPAND clinical trial results; potential approval of AeroForm by the U.S. Food and Drug Administration, or FDA; and the increased awareness of and commercial potential of AeroForm. These forward-looking statements are based on AirXpanders' current expectations and inherently involve significant risks and uncertainties. AirXpanders' actual results and timing of events could differ materially from those anticipated in such forward-looking statements, and as a result of these risks and uncertainties, which include, without limitation, risks related to  any delays or inability to obtain and maintain regulatory approval of AeroForm in the United States; the uncertain clinical development process, including adverse events or the fact that the FDA may dispute or interpret differently clinical results obtained to date from the XPAND trial; or the market potential for AeroForm. AirXpanders undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Logo - http://photos.prnewswire.com/prnh/20141205/162738LOGO

SOURCE AirXpanders, Inc.

Related Links

http://www.airxpanders.com